Prof Marc van den Eynde, digestive oncologist at Cliniques Universitaires Saint-Luc in Brussels, presented the results of the AVETUXIRI phase II study with the combination of avelumab, cetuximab and irinotecan for the treatment of refractory microsatellite stable metastatic colorectal cancer. Despite good tolerability, the AVETUXIRI trial did not reach its efficacy endpoint. The immunoscore, determined by immunofluorescence (CD3, CD8 densities) on baseline metastasis biopsies, could be a predictive biomarker for selecting patients with potential treatment benefits.
With the educational support of:
 |
 |